Elegen is a company that provides NGS verified, cell-free DNA synthesis with linear DNA from 1 to 7kb, offering high accuracy and fast delivery for synthetic biology workflows.

Elegen

We are now at the dawn of the synthetic biology revolution, which will spawn new applications, markets, and business models, improving human lives in countless ways. This revolution will be driven by new technologies that enable DNA writing at speed and scale.

To catalyze this revolution, Elegen is creating a suite of ground-breaking technologies to achieve DNA writing with unparalleled speed, cost, and quality. Elegen is unlocking the power to reprogram biology and create biologic solutions in order to solve some of humanity’s greatest challenges.

Founded and led by Dr. Matthew Hill and located in San Carlos, CA, Elegen is a stealth-mode company that is well capitalized by top life science investors, including Andreessen Horowitz, 8VC, and KdT. The company is advised and staffed by leading biotechnology scientists and entrepreneurs, including Dr. Marc Unger, inventor of the Nanoflex™ valve and former CSO of Fluidigm. Dr. Hill has a PhD from Stanford and a proven track record of advancing innovative technologies from invention to commercial success. 

Sahsen Ventures

Alix Ventures

ELEGEN

#TeamElegen welcomes @Tony Cox, Ph.D. as Principal Scientist! Tony brings extensive #synbio experience and a proven record of conceiving, developing and implementing innovative solutions on both an experimental and commercial high-throughput scale - a great fit for advancing ELEGEN's next-gen ENFINIA DNA scaleup development! #WelcometotheTeam, Tony!

#hiring #growing #BayAreaJobs #SanFrancisco #employeeappreciation

The RNA Therapeutics - From Concept to Clinic Conference is in full swing!  Stop by ELEGEN Booth 12 to learn about ENFINIA next-generation DNA - long, complex, clonal-quality DNA, shipped in 6-8 days and ready for direct use in your workflows, no cloning required. You can reliably count on ENFINIA DNA to meet your deadlines.

#RNAtherapeutics #nextgenDNA #EnfiniaDNA #mRNAvaccines RNA Therapeutics Institute at UMass Chan Medical School #RNATx

Join the team that is making next-gen DNA a reality! Our R&D and Operations groups continue to grow. Innovative technology, great culture, awesome people. Check out our open positions & apply: https://hubs.ly/Q02CP7vc0

#synbio  #biotech #SanFrancisco #BayAreaJobs #Hiring

Yesterday was International Women in Engineering Day, but we celebrate these women and the awesome skills they bring to #TeamElegen and #cellfreesynthesis every day! We ♥️ their knowledge, dedication, passion, and teamwork that enhance our products, technology, and work culture. 👏🎉

#INWED24 #EnhancedbyEngineering 
Marion Meunier, Nadiya Sitdykova, Iris HC Lin, Nidhi Gupta,
Radhika Dalal, Kellie King, Sukhvinder Kaur, Galit Meshulam-Simon

ENFINIA DNA is #NextGen DNA:
✅ Long (≤7 kb)
✅ NGS-verified
✅ High complexity
✅ ≥95% purity
✅ Reliable, fast turnaround (6-8 days)

With our cell-free DNA production tech, ENFINIA linear DNA ships ready-to-use with minimal or no cloning. 

ELEGEN's not your grandfather’s gene synthesis provider. 

Ready to get started? https://hubs.ly/Q02CvsCL0
#genesynthesis #EnfiniaDNA #cellfreesynthesis #DNAinnovation

This month’s #EmployeeSpotlight is on Kellie King, Sr. Research Associate. Working on the molecular biology team, she loves testing new ideas and streamlining processes to be as efficient as possible. We're #LuckytoHaveYou on #TeamElegen!👏🎉

Learn more about Kelly: https://bit.ly/3RBa0R3

#EmployeeAppreciation #BayAreaJobs

Metric
Company Name	Elegen
Symbol
MSH ID	COM:ELEGENBIO
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count	73
Website	elegenbio.com
LinkedIn	elegenbio
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ELEGENBIO

Elegen

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue